recombinant mltβr  (R&D Systems)

Journal: Cancer cell

Article Title: MUTANT EZH2 INDUCES A PRE-MALIGNANT LYMPHOMA NICHE BY REPROGRAMMING THE IMMUNE RESPONSE

doi: 10.1016/j.ccell.2020.04.004

Figure Lengend Snippet: A. Mixed chimera mice (n=5) immunized with NP-OVA were treated with two doses of 100 µg lymphotoxin mLTβR-mIgG1 or control IgG antibody.

Article Snippet: In the experiments where interactions with Tfh or FDC were blocked in vivo , mice received 100 μg anti CD40L antibody i.v. (clone MR-1, BioXCell BE0017), 150 μg anti ICAM-1 antibody i.p. (clone YN1/1.7.4, BioXCell BE0020), 100 μg recombinant mLTβR (a fusion protein of lymphotoxin β receptor and Fc region of mouse IgG, which acts as inhibitor of transmembrane LTβR) i.v. (R&D Systems 1008-LR), or control IgG antibodies (BioXCell BE0091 and BE0090).

Techniques: Control

Journal: Cancer cell

Article Title: MUTANT EZH2 INDUCES A PRE-MALIGNANT LYMPHOMA NICHE BY REPROGRAMMING THE IMMUNE RESPONSE

doi: 10.1016/j.ccell.2020.04.004

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: In the experiments where interactions with Tfh or FDC were blocked in vivo , mice received 100 μg anti CD40L antibody i.v. (clone MR-1, BioXCell BE0017), 150 μg anti ICAM-1 antibody i.p. (clone YN1/1.7.4, BioXCell BE0020), 100 μg recombinant mLTβR (a fusion protein of lymphotoxin β receptor and Fc region of mouse IgG, which acts as inhibitor of transmembrane LTβR) i.v. (R&D Systems 1008-LR), or control IgG antibodies (BioXCell BE0091 and BE0090).

Techniques: Control, Blocking Assay, Recombinant, Adjuvant, Plasmid Preparation, Binding Assay, Staining, RNA Library Preparation, MicroChIP Assay, Sequencing, Microarray, Knock-In, Software, Gene Expression, Targeted Proteomics